Literature DB >> 15048076

Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle.

Senthil K Radhakrishnan1, Claudine S Feliciano, Feridoon Najmabadi, Andrea Haegebarth, Eugene S Kandel, Angela L Tyner, Andrei L Gartel.   

Abstract

p21 is a potent inhibitor of cyclin-dependent kinases capable of arresting cell cycle progression. p21 is primarily regulated at the transcriptional level by several transcription factors, including p53. Previously, we reported that certain members of the E2F family of transcription factors may activate p21 transcription via a p53-independent mechanism. To further elucidate the consequences of E2F-1-regulated induction of p21, we developed cell lines with a tamoxifen-dependent form of E2F-1. We confirmed direct interaction of E2F-1 with the proximal region of the p21 promoter. Interestingly, elevated E2F-1 activity was sufficient to arrest a substantial subset of cells in S phase and this effect was correlated to and dependent on the induction of p21 protein. Since E2F proteins control genes required for cell cycle progression and are activated by various oncogenic events, we believe that the p21-dependent arrest described in this report represents an additional mechanism that guards against unrestricted cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048076     DOI: 10.1038/sj.onc.1207571

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  43 in total

Review 1.  Multiple functions of p21 in cancer radiotherapy.

Authors:  Yanbei Kuang; Jian Kang; Hongbin Li; Bingtao Liu; Xueshan Zhao; Linying Li; Xiaodong Jin; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-05       Impact factor: 4.553

2.  Expression level is a key determinant of E2F1-mediated cell fate.

Authors:  Igor Shats; Michael Deng; Adam Davidovich; Carolyn Zhang; Jungeun S Kwon; Dinesh Manandhar; Raluca Gordân; Guang Yao; Lingchong You
Journal:  Cell Death Differ       Date:  2017-02-17       Impact factor: 15.828

3.  Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells.

Authors:  Yuting Yao; Lu Li; He Zhang; Renbing Jia; Bo Liu; Xiaoping Zhao; Leilei Zhang; Guanxiang Qian; Xianqun Fan; Shengfang Ge
Journal:  Oncol Lett       Date:  2012-04-17       Impact factor: 2.967

4.  Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition.

Authors:  Can Liu; Yan Zeng; Long-Hai Dai; Tian-Yu Cai; Yue-Ming Zhu; De-Quan Dou; Lan-Qing Ma; Yuan-Xia Sun
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

5.  Functional interplay between E2F1 and chemotherapeutic drugs defines immediate E2F1 target genes crucial for cancer cell death.

Authors:  David Engelmann; Susanne Knoll; Daniel Ewerth; Marc Steder; Anja Stoll; Brigitte M Pützer
Journal:  Cell Mol Life Sci       Date:  2009-12-15       Impact factor: 9.261

Review 6.  p53 and E2f: partners in life and death.

Authors:  Shirley Polager; Doron Ginsberg
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

7.  p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell.

Authors:  Junxia Wei; Jiang Zhao; Min Long; Yuan Han; Xi Wang; Fang Lin; Jihong Ren; Ting He; Huizhong Zhang
Journal:  BMC Cancer       Date:  2010-11-19       Impact factor: 4.430

8.  Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.

Authors:  B Nitzsche; C Gloesenkamp; M Schrader; M Ocker; R Preissner; M Lein; A Zakrzewicz; B Hoffmann; M Höpfner
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

9.  E2F1 mediates DNA damage and apoptosis through HCF-1 and the MLL family of histone methyltransferases.

Authors:  Shweta Tyagi; Winship Herr
Journal:  EMBO J       Date:  2009-09-17       Impact factor: 11.598

10.  FoxM1 is a general target for proteasome inhibitors.

Authors:  Uppoor G Bhat; Marianna Halasi; Andrei L Gartel
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.